Compare AbCellera Biologics Inc (ABCL) vs AMC ENTERTAINMENT HOLDINGS, INC. (AMC) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

AMC trades at $1.72, down 8.99% in the last session amid dilution concerns from recent equity offerings. The stock shows bearish technical signals with negative cash flows and a net loss of $632.4M in 2025. Recent news highlights summer box office strength but ongoing investor worries about share dilution and profitability. The company's debt remains high at $4.01B, though revenue reached $4.85B in 2025.

Outlook remains challenged by persistent losses and high leverage, though diversification into live events offers growth potential. Key risks include dilution from equity sales and weak cash generation. Analyst consensus is mixed with a $1.85 price target, suggesting limited upside from current levels amid fundamental headwinds.